Phase I clinical trial of temsirolimus and perifosine for recurrent glioblastoma

PURPOSE: Malignant glioma (MG) is the most deadly primary brain cancer. Signaling though the PI3K/AKT/mTOR axis is activated in most MGs and therefore a potential therapeutic target. The mTOR inhibitor temsirolimus and the AKT inhibitor perifosine are each well‐tolerated as single agents but with li...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaley, Thomas J., Panageas, Katherine S., Pentsova, Elena I., Mellinghoff, Ingo K., Nolan, Craig, Gavrilovic, Igor, DeAngelis, Lisa M., Abrey, Lauren E., Holland, Eric C., Omuro, Antonio, Lacouture, Mario E., Ludwig, Emmy, Lassman, Andrew B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7187704/
https://www.ncbi.nlm.nih.gov/pubmed/32293798
http://dx.doi.org/10.1002/acn3.51009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7187704/
https://www.ncbi.nlm.nih.gov/pubmed/32293798
http://dx.doi.org/10.1002/acn3.51009

Ejemplares similares